链球菌制剂SY914体外抗瘤实验研究

Anti-tumor Experimental Research of The Streptococcal Preparation (SY 914) in Vitro

为研究ＳＹ９１４β－溶血性链球菌制剂的体外抗瘤作用及作用机制，用ＳＲＢ法对抗癌链球菌制剂ＳＹ９１４作用于人癌细胞株（ＳＧＣ－７９０１，Ａ５４９，ＴＣＡ８１１３，ＫＢ）进行体外抑瘤实验研究，并通过电镜对ＳＹ９１４作用于ＳＧＣ７９１０的过程进行超微结构观察，Ｈ３掺入实验观察ＳＹ９１４对蛋白合成的影响．结果：ＳＹ９１４对４个细胞株具有体外生长抑制作用，ＩＣ５０分别为６２１３（ＳＹ７９０１），１６１７（Ａ５４９），１１５２（ＴＣａ８１１３），１９６（ＫＢ）［ｍｇ／Ｌ］．电镜观察发现ＳＹ９１４作用于瘤细胞后、胞浆内核蛋白体数量明显减少，细胞溶解坏死，Ｈ３掺入实验提示ＳＹ９１４具有显著抑制肿瘤细胞蛋白质合成的作用．结果显示：ＳＹ９１４具有直接抑制肿瘤细胞生长的作用。

In order to identify anti-tumor action and action mechanism in vitro of SY914 that is a lyophilized preparation of β-streptococcus,.SRB assay was used to research on following human tumor cell lines:SGC7901,A549,TCA8113 and KB.Meanwhile,the process of ultramicrostructural changes of that SY914 acted on SGC7901 was observed under Transmission Electric Microscopic (TEM),and H3-TdR incorporation assay was used to find out SGC7901's influence on protein synthesis.The results showed that SY914 had direct cytotoxicity and growth-inhibition to all experimental human tumor cell lines.The 50% growth-inhibition dose (IC50) to SGC7901,A549,TCA8113 and KB was 62 13 mg/L,18 17 mg/L,11 52 mg/L,and 196 mg/L separately.Through TEM observation,we found the number of the free nucleoglucoprotein bodies of tumor cell decreased obviously caused by SY914 action.The result of H 3——TdR incorporation assay also showed that the protein synthesis of SGC7901 was significantly inhibited by SY914.These results suggested that SY914 can inhibit the growth of tumor cell directly,and probable mechanism is that protein synthesis was inhibited.